Loading clinical trials...

Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 2NCT00552188

Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event

The purpose of this study is to determine the effect of VIA-2291 as compared to placebo on vascular inflammation following 24 weeks of dosing.

Lead sponsor: Tallikut Pharmaceuticals, Inc.•2 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

RECRUITINGPhase 4

Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI

NCT04695106 · Atrial Fibrillation, Antithrombotic Therapy, and more

RECRUITING

Florbetaben for Imaging of Vascular Amyloid

NCT06091319 · Acute Coronary Syndrome, Stroke, and more

RECRUITINGNA

Artificial Intelligence-Driven Medipixel Fractional Flow Reserve Versus Invasive Fractional Flow Reserve-Guided PCI Trial (AIM-FFR Trial)

NCT07329699 · Coronary Artery Disease, Chronic Coronary Syndrome, and more

RECRUITINGNA

Point-of-Care Troponin Testing in the Emergency Department

NCT06845826 · Acute Coronary Syndromes

RECRUITING

Drug-Coated Balloon Primary PCI in ST-Segment Elevation Myocardial Infarction

NCT07436429 · Myocardial Infarction (MI), ST-Elevation Myocardial Infarction, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 9, 2013Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment52

Start dateOct 2007

Last updatedAug 9, 2013

Condition

Acute Coronary Syndrome

Locations shown

VIA Pharmaceuticals

San Francisco, California

VIA Pharmaceuticals

Princeton, New Jersey

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 9, 2013Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions